SYNTi
SYNTi is a PDZ domain inhibitor targeting the syndecan/syntenin protein-protein Interaction. SYNTi exhibits an IC50 value of 400 nM and ligand efficiency (LE) value of 0.24. SYNTi can be used for breast cancer research[1].
Product Specifications
UNSPSC
12352005
Target
SDCBP
Type
Reference compound
Related Pathways
Stem Cell/Wnt
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/synti.html
Solubility
10 mM in DMSO
Smiles
O=C1N(CC2=CC(Br)=CC=C21)[C@H](C(N[C@H](C(O)=O)C)=O)CC3=CC=C(C=C3)C4=CC(C(C)=O)=CC=C4F
Molecular Formula
C28H24BrFN2O5
Molecular Weight
567.40
References & Citations
[1]Hoffer L, et al. Discovery of a PDZ Domain Inhibitor Targeting the Syndecan/Syntenin Protein-Protein Interaction: A Semi-Automated "Hit Identification-to-Optimization" Approach. J Med Chem. 2023 Apr 13;66 (7) :4633-4658.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS642576-01 0.2 mL
ZNF124, NT (ZNF124, Zinc finger protein 124, Zinc finger protein HZF-16)
Sign In for Pricing
View Details MBS642576-02 5x 0.2 mL
ZNF124, NT (ZNF124, Zinc finger protein 124, Zinc finger protein HZF-16)
Sign In for Pricing
View Details 
TRC-B419078-250MG 250 mg
1,4-Bis(3-(4-(7-chloroquinolin-4-yl)piperazin-1-yl)propyl)piperazine
Sign In for Pricing
View Details